Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Rezdiffra’s Market Performance Rezdiffra has demonstrated strong market acceptance since its launch, with prescription rates steadily increasing.

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.